A photo of Punam Malik.

Punam Malik, MD


  • Director, Cincinnati Comprehensive Sickle Cell Center
  • Program Leader, Hematology and Gene Therapy Program
  • Marjory J. Johnson Chair, Gene and Cell Therapy
  • Professor, UC Department of Pediatrics

About

Location

Insurance Information

Cincinnati Children's strives to accept a wide variety of health plans. Please contact your health insurance carrier to verify coverage for your specific benefit plan.

View Insurance Information

Publications

Differential CXCR4 expression on hematopoietic progenitor cells versus stem cells directs homing and engraftment. Felker, S; Shrestha, A; Bailey, J; Pillis, DM; Siniard, D; Malik, P. JCI insight. 2022; 7.

NRASQ61R mutation in human endothelial cells causes vascular malformations. Boscolo, E; Pastura, P; Schrenk, S; Goines, J; Kang, R; Pillis, D; Malik, P; Le Cras, TD. Angiogenesis. 2022.

Successful use of veno-venous extracorporeal membrane oxygenation for acute chest syndrome in a child with sickle cell disease and SARS-CoV-2. Koh, W; Malik, P; Whitehead, J; Morales, DL S; Hayes, D. Pediatric Pulmonology. 2022; 57:1096-1099.

Safety and Efficacy of Aru-1801 in Patients with Sickle Cell Disease: Early Results from the Phase 1/2 Momentum Study of a Modified Gamma Globin Gene Therapy and Reduced Intensity Conditioning. Grimley, M; Asnani, M; Shrestha, A; Felker, S; Lutzko, C; Arumugam, PI; Witting, S; Knight-Madden, J; Niss, O; Quinn, CT; et al. Blood. 2021; 138:3970-3970.

Towards access for all: 1st Working Group Report for the Global Gene Therapy Initiative (GGTI). Adair, JE; Androski, L; Bayigga, L; Bazira, D; Brandon, E; Dee, L; Deeks, S; Draz, M; Dubé, K; Dybul, M; et al. Gene Therapy. 2021.

Rapid and automated quantitation of dense red blood cells: A robust biomarker of hydroxyurea treatment response. Sadaf, A; Quinn, CT; Korpik, JB; Pfeiffer, A; Reynaud, M; Niss, O; Malik, P; Ware, RE; Kalfa, TA; McGann, PT. Blood Cells, Molecules, and Diseases. 2021; 90.

Early initiation of hydroxyurea (hydroxycarbamide) using individualised, pharmacokinetics-guided dosing can produce sustained and nearly pancellular expression of fetal haemoglobin in children with sickle cell anaemia. Quinn, CT; Niss, O; Dong, M; Pfeiffer, A; Korpik, J; Reynaud, M; Bonar, H; Kalfa, TA; Smart, LR; Malik, P; et al. British Journal of Haematology. 2021; 194:617-625.

Cardiac pathophysiology in sickle cell disease. Gbotosho, OT; Taylor, M; Malik, P. Journal of Thrombosis and Thrombolysis. 2021; 52:248-259.

Implementation of near-universal hydroxyurea uptake among children with sickle cell anemia: A single-center experience. Karkoska, K; Todd, K; Niss, O; Clapp, K; Fenchel, L; Kalfa, TA; Malik, P; Quinn, CT; Ware, RE; McGann, PT. Pediatric Blood and Cancer. 2021; 68.

FT-4202, an oral PKR activator, has potent antisickling effects and improves RBC survival and Hb levels in SCA mice. Shrestha, A; Chi, M; Wagner, K; Malik, A; Korpik, J; Drake, A; Fulzele, K; Guichard, S; Malik, P. Blood Advances. 2021; 5:2385-2390.

Patient Ratings and Comments

All patient satisfaction ratings and comments are submitted by actual patients and verified by a leading independent patient satisfaction company, NRC Health. Patient identities are withheld to ensure confidentiality and privacy. Only those providers whose satisfaction surveys are administered through Cincinnati Children’s Hospital Medical Center are displayed. Click here to learn more about our survey